Author Correction: Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease
Crossref DOI link: https://doi.org/10.1038/s41598-018-31455-w
Published Online: 2018-09-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Chen, Shuchun
Yu, Seong-Jin
Li, Yazhou
Lecca, Daniela
Glotfelty, Elliot
Kim, Hee Kyung
Choi, Ho-Il
Hoffer, Barry J.
Greig, Nigel H.
Kim, Dong Seok
Wang, Yun
Text and Data Mining valid from 2018-09-12
Version of Record valid from 2018-09-12
Article History
First Online: 12 September 2018